miR-544a promotes the invasion of lung cancer cells by targeting cadherina 1 in vitro
Xiaomei Mo,1,2,* Fenghua Zhang,2,* Hui Liang,2 Ming Liu,1 Huahui Li,3 Haiping Xia3
1Key Laboratory of Marine Drugs, Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, 2Qingdao Women and Children Hospital, 3Department of Laboratory Medicine, Qingdao Municipal Hospital, Qingdao, People's Republic of China
*These authors contributed equally to this work
Objective: To find out the effect of miR-544a on the invasion of lung cancer cells and to explore the underlying molecular mechanisms.
Methods: Micro-ribonucleic acid (miRNA) expression in two different invasive lung cancer cell lines 95C (low invasive ability) and 95D (high invasive ability) was analyzed by miRNA microarray and real-time quantitative polymerase chain reaction (PCR); miR-544a mimic was transfected to 95C, and its invasion ability was detected by transwell migration assay; we predicted the candidate miRNA target genes by TargetScan (Whitehead Institute for Biomedical Research, Cambridge, MA, USA) software and verified the target genes by Western blot.
Results: The expression of miR-544a was significantly increased in 95D in miRNA microarray and quantitative PCR tests (P<0.05). After being transfected with miR-544a mimic, the invasion ability of 95C was enhanced (P<0.01). Moreover, transfection with miR-544a inhibitor decreased the invasion ability of 95D (P<0.01). miR-544a possibly combined with CDH1 (E-cadherin) predicted by the TargetScan analysis. 95C with miR-544a mimic reduced the expression of CDH1 and improved the expression of vimentin, while 95D with miR-544a inhibitor improved the expression of CDH1 and reduced the expression of vimentin.
Conclusion: miR-544a can promote the invasion of non-small cell lung cancer by downregulation of CDH1 and upregulation of vimentin.
Keywords: NSCLC, non-small cell lung cancer, E-cadherin, microRNA, EMT
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]